Isomatsu Y, Kaburagi Y, Jinbo S, Nashimo T, Miki M, Yamanaka H
Gan To Kagaku Ryoho. 1983 Sep;10(9):1958-62.
In order to investigate the effect of Diacetyl-glucaro-(1-4) (6-3) dilactone to prevent post-operative recurrence of bladder cancer, we estimated the recurrent rate of 34 patients who were diagnosed as having bladder cancer and treated by several surgical methods and oral administration of the drug in our hospital during 1971 and 1980. The following results were obtained: The 6, 12, 18, 24, 30, 36 and over 36 months-recurrent rates were 3.1%, 26.4%, 32.5%, 32.5%, 32.5%, 46% and 46%. In control group, they were 10%, 23.3%, 34.8%, 46.2%, 73.1%, 73.1% and 100% In a 24 month follow-up, there was no difference of recurrent rate between the group receiving the drug and control group: a recurrent rate of administrated group was lower than that of the control after 24 months. The recurrent rate of the group receiving Diacetyl-glucaro-(1-4) (6-3) dilactone combined with instillation was lower in a 2 year follow-up. It was anticipated that the combined therapy (Diacetyl-glucaro-(1-4) (6-3) dilactone administration and intravesical instillation of anticancer drugs) was useful in order to prevent recurrence of bladder cancer.
为研究二乙酰 - 葡糖醛酸 -（1 - 4）（6 - 3）双内酯预防膀胱癌术后复发的效果，我们评估了1971年至1980年间在我院被诊断为膀胱癌并接受多种手术方法及该药物口服治疗的34例患者的复发率。获得以下结果：6个月、12个月、18个月、24个月、30个月、36个月及36个月以上的复发率分别为3.1%、26.4%、32.5%、32.5%、32.5%、46%和46%。对照组的相应复发率分别为10%、23.3%、34.8%、46.2%、73.1%、73.1%和100%。在24个月的随访中，用药组和对照组的复发率无差异：24个月后用药组的复发率低于对照组。在2年随访中，接受二乙酰 - 葡糖醛酸 -（1 - 4）（6 - 3）双内酯联合膀胱灌注治疗组的复发率较低。预计联合治疗（二乙酰 - 葡糖醛酸 -（1 - 4）（6 - 3）双内酯给药及膀胱内灌注抗癌药物）对预防膀胱癌复发有效。
